It’s exciting to think we’re on the brink of a genomic revolution in health care. But just because new technology becomes available, it doesn’t mean it should automatically be publicly funded.
CRISPR harnesses the natural defence mechanisms of some bacteria to cut human DNA strands. Then the DNA strand either heals itself or we inject new DNA to mend the gap. This is gene editing.
In 2030, there is a boom in precision medicine, where diseases – from cancer to dementia – are defined and targeted more specifically with a focus on their molecular makeup.
Hua Lu, University of Maryland, Baltimore County y Linda Wiratan, University of Maryland, Baltimore County
Precisely calibrated timekeepers are found in organisms from all domains of life. Biologists are studying how they influence plant/pathogen interactions – what they learn could lead to human medicines.
People with the same condition can respond differently to the same treatment. This is why personalised treatment is so important in all fields of medicine, including psychology.
A field called epigenomics looks at chemical modifications that do not change our DNA sequence but can affect gene activity. What are the limitations, and can biomedicine use this to our advantage?
Diabetes, which afflicts 29 million people in the U.S., remains a difficult disease to treat. Read how an algorithm devised by MIT researchers could help.
Although genomics research has the potential to revolutionize medicine, it has limitations. It may not do much to prevent many of the leading causes of death.
Lowering the threshold for FDA approval and feeding the agency less rigorous information will increase the likelihood of approvals of unsafe or ineffective drugs and devices.
The outgoing president leaves behind some solid accomplishments in the world of science, tech and medicine. But the biggest departure from his predecessors might have been in his approach.
In developed countries, the main causes of preterm deaths are well known and studied.But in low resource countries, the causes are much less understood.
Precision public health has the potential to transform the global health sphere by ensuring that the right interventions are brought to the right people in the right places.
We should heed concerns about how private genetic data banks are used and accessed before we enable a system where the future of public genetic research lies in private hands.
How much privacy are we willing to give up in the name of cutting-edge science? And do we care about the kinds of research that will be done with our donations?
Honorary Enterprise Professor, School of Population and Global Health, and Department of General Practice and Primary Care, The University of Melbourne
Professor of Breast Cancer Research, Institute of Health and Biomedical Innovation and School of Biomedical Sciences,, Queensland University of Technology